

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Express Mail No.:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hong Jin *et al.*

Confirmation No.: 8169

Application No.: 09/724,388

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: Lucas, Zachariah

For: RECOMBINANT RSV EXPRESSION SYSTEMS AND VACCINES Attorney Docket No.: 7682-051-999

**DECLARATION OF DAVID K. CLARKE
UNDER 37 C.F.R. § 1.131**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, DAVID K. CLARKE, who resides at 3205 Whispering Hills, Chester, New York 10918, do declare that:

1. I am a co-inventor of the invention described in the above-identified application and as claimed in pending claims 7 to 21 (annexed hereto as Exhibit A1).
2. The above-identified application and pending claims relate to genetically manipulated, infectious, replication-competent, non-segmented, negative-strand RNA viruses wherein the viral genome has been modified, *e.g.*, the genome contains deletions or insertions. The invention and pending claims encompass genetically manipulated paramyxoviruses in which the viral genome has been modified to result in a packaged infectious virion with an attenuated phenotype, *i.e.*, the virus is able to go through only one or a few rounds of replication in the host. The invention encompasses genetically manipulated RSV, vaccines comprising genetically manipulated RSV and methods for generating genetically manipulated RSV. The application claims priority to a series of

applications including earlier filed application no. 09/161,122 filed September 25, 1998, which, in turn, is a continuation-in-part of our earlier application no. 08/316,439, filed September 30, 1994 (Grand-Parent Application, attached hereto as Exhibit A2, now U.S. Patent No. 5,840,520, issued November 24, 1998).


3. Annexed hereto as Exhibit B is a copy of a page from my laboratory notebook describing a research plan to genetically manipulate the genome of RSV to result in a virion with an attenuated phenotype. Such genetic manipulations include deletions and insertions of sequences in the viral genome. Although the date on the copy has been redacted, the notebook page is dated prior to January 10, 1994. Thus, demonstrating that prior to January 10, 1994, I had conceived a genetically manipulated, replication-competent, infectious, non-segmented negative strand RNA virus having an attenuated phenotype as described in the Grand Parent application and described and claimed in the instant application.

4. Annexed hereto as Exhibits C through E are copies of pages from my laboratory notebooks that demonstrate that I or person(s) acting under my direction and supervision worked with diligence from the conception of the invention up to the filing date of the Grand Parent application to reduce the claimed invention to practice. This is evidenced by the facts described below and by the attached exhibits.

5. Exhibits C to E are true copies of my laboratory notebooks that describe experiments relating to, among others, the generation of a full length cDNA encoding the genome of RSV. The pages of the laboratory notebooks are numbered consecutively for ease of reference. The references to pages in the laboratory notebooks are

to the production numbers stamped at the bottom right corner of the pages in the notebooks. The dates in the laboratory notebooks have been redacted. Further, references to events that would lead to the date of the entry into the laboratory notebook have also been redacted. The laboratory notebooks document experiments that were conducted during the time period from briefly before the date of the conception document until the filing date of the Grand Parent application.

6. In particular, the laboratory notebooks document the isolation of genomic RSV RNA, RT-PCR amplification of fragments of the RSV genome, optimization of growth cultures of RSV, the subcloning of the RT-PCR fragments of the RSV genome in different cloning vectors and the ligation of the different RT-PCR fragments to obtain a cDNA encoding the full length genome of RSV. The fragments of the RSV genome that are mentioned in the laboratory notebooks are set forth in the following genomic restriction map of RSV. Restriction enzyme sites are shown on above the line representing the genome and the numbers below the line refer to the approximate sizes of the fragments in kilobasepairs. In this declaration, DNA fragments are referred to by the name of the flanking restriction sites followed by the approximate length of the fragment. For example, the first fragment at the 3' end of the virus is designated BstU/Hha-3.5. Synonyms of the DNA fragments are listed in the respective paragraphs that describe the work relating to the different DNA fragments. The map below also shows how the different DNA fragments were to be assembled to obtain the full length RSV cDNA.



Genomic Restriction Map of RSV

7. The following paragraphs explain the type of experiments to obtain the different DNA fragments shown in the diagram above and the experiments to assemble these fragments into a full-length RSV cDNA; references in the following paragraphs are to production numbers in Exhibits C to E. In general, the entries in connection with obtaining the DNA fragments relate to RT-PCR amplification of the fragment, purification of the amplified DNA material, ligation into a cloning vector, transfection into bacteria, preparation of plasmid DNA from the transfected bacteria, and restriction analysis of the plasmid DNA.

7a. Work relating to the growth of RSV, infection of different cell types with RSV, the harvest and purification of virus, and the purification of genomic RNA of RSV are described at production nos. 47-65, 67-70, 72-79, 81, 95, 105, 110, 113, 117, 121-125, 127, 133, 137-144, 146, 148, 150-151, 153, 155, 169, 176-177, 188, 193, 212, 249, 269, 322, and 353-354 of my laboratory notebooks. These entries also relate to obtaining RS virus stocks from different sources, the optimization of growth conditions for RSV, testing of different cell lines for virus replication, optimization of virus preparation, and the purification of genomic RNA from the virus.

7b. Work relating to the performance of RT-PCR to obtain DNA fragments that encode parts of the viral genome are described at production nos. 65-66, 83-84, 87, 89, 90, 157, 160-165, 170, 172, 173, 179-180, 205, 242, 246-247, 282, and 393-394 of my laboratory notebooks. These entries also relate to obtaining the reagents and biochemicals for conducting RT-PCR, designing of primers, designing of cloning strategies, and the optimization of the conditions for the performance of RT-PCR. Work relating to the preparation of cloning vectors for subcloning of the RT-PCR fragments is described at production nos. 115-116 (puc19),

7c. Work relating to the RT-PCR amplification and the subcloning of the BstU/Hha-3.6 fragment (also referred to as "BstU/Hha" and "3.5K" and "3.6K" and "3.7K") is described at production nos. 264, 270, 272, 274, 276-277, 279, 281, 298, 301-302, 322-323, 325, 328, 339, 343, 367, 369-371, 378, and 381-382 of my laboratory notebooks. These entries also relate to large scale plasmid preparation of the cloned fragment.

7d. Work relating to the RT-PCR amplification and the subcloning of the Hha/Xho-0.9 fragment (also referred to as "0.9K" and "H/Xho" and "Hha/Xho" and "clone 8") is described at production nos. 327-331, 336-337, 345-350, 352, 361-362, 366-368, 371, 376, 378-380, 382, 386-387, and 392 of my laboratory notebooks. These entries also relate to the development of alternative cloning strategies, and the evaluation of restriction analysis.

7e. Work relating to the RT-PCR amplification and the subcloning of the Xho/Xca-1.35 fragment (also referred to as "1.3K" (370) and "Xho/Xca" and "clone 2") is described at production nos. 295-298, 299, 301, 331, 336-337, 345-350, 352, 358-368, 370, 374, 377-380, 382, 386-387, 393, 399, 423, 426-427, 429-432, 434, 459-461, 465-467, 471-

473, 475-476, and 481-487 of my laboratory notebooks. These entries also relate to the development of alternative cloning strategies, and the evaluation of restriction analysis.

7f. Work relating to the RT-PCR amplification and the subcloning of the Xca/BamHI-2.68 fragment (also referred to as "Xca/Bam" and "Bam/Xca" and "X/B" and "2.6K" and "2.7K") is described at production nos. 261-262, 264, 268, 270-271, 274-275, 306, 322, 343, 369-370, 373-374, and 377-378 of my laboratory notebooks.

7g. Work relating to the RT-PCR amplification and the subcloning of the BamHI/SphI-2.25 fragment (also referred to as "BamHI/SphI" and "Bam/Sph" and "2.25Kb" or "2.25K") is described at production nos. 258-260, 268, 270-271, 274-275, 305-306, 343, 354-357, 407-411, 433, 457, 459, 461-464, 472, 475, 480, 484, and 486-490 of my laboratory notebooks. These entries also relate to restriction mapping of the BamHI/SphI-2.25 fragment.

7h. Work relating to the RT-PCR amplification and the subcloning of the SphI/PmlI-1.5 fragment (also referred to as "1.5K") is described at production nos. 250-254, 256-257, 259-260, 263, 266-267, 305, 343, 354-357, 409-410, 412, 418-420, 422-423, 425-434, 457, 461-464, 486, and 488 of my laboratory notebooks. These entries also relate to restriction mapping of the SphI/PmlI-1.5 fragment.

7i. Work relating to the RT-PCR amplification and the subcloning of the PmlI/5'end-3 fragment (also referred to as "3K" and "3K sure") is described at production nos. 179-180, 189-190, 193-196, 198, 298, 301-303, 309, 311, 316, 343, 407-409, 411-412,

418-424, 433, and 457 of my laboratory notebooks. These entries also relate to large scale plasmid preparation and the restriction analysis of the plasmid DNA.

7j. Work relating to the RT-PCR amplification and subcloning of the BamHI/PmlI-3.8 fragment (also referred to as "3.8Kb") is described at production nos. 181, 185, 194, 196, 197, 201-202, 204, 207-210, 214-216, 240-242, and 243 of my laboratory notebooks. These entries also relate to designing of primers to amplify the BamHI/PmlI-3.7 fragment.

7k. Work relating to the RT-PCR amplification and subcloning of the HhaI/XcaI-2.28 fragment (also referred to "2.3k" and "Hha/Xca" and "H/Xca" and "Sure 2.3" and "H/X") is described at production nos. 261-262, 268, 275-281, 285, 287-294, 299-300, 305, 307, 309, 311-321, 324, 327-330, 332, 334-336, 337, 339-345, 372-374, and 388-391 of my laboratory notebooks. These entries also relate to designing of primers to amplify the HhaI/XcaI-2.28 fragment and the development of alternative cloning strategies, such as the use of different competent bacterial cells for the propagation of the plasmid DNA.

7l. Work relating to the RT-PCR amplification and subcloning of the BstUI/XhoI-4.5 fragment (this fragment is also referred to as "4.4K") is described at production nos. 325-326, 414-417, and 421 of my laboratory notebooks.

7m. Work relating to the RT-PCR amplification and subcloning of the Xho/BamHI-4 fragment (also referred to as "4K" and "Xho/Bam") is described at production nos. 205-207, 209-211, 214, 379, and 383-384 of my laboratory notebooks.

7n. Work relating to the generation of the leader and trailer regions of the RSV is described at production nos. 92-94, 113-114, 127, 129-136, 138, 139, 283-284, and 405 of my laboratory notebooks.

7o. Work relating to the ligation of the BstU/Hha-3.6 fragment, the HhaI/XcaI-2.28, and the Xca/BamHI-2.68 fragment to result in BstUI/BamHI-8.5 are described at production nos. 347-352 of my laboratory notebooks.

7p. Work relating to the ligation of the BstU/Hha-3.6 fragment and the Hha/Xho-0.9 fragment to obtain a the BstU/Xho-4.4 fragment (also referred to as "4.4k") is described at production nos. 391-392, 395-398, 400-401, 403, 406, 413, 469, 471, 473, 476-482, 484-485, 489-490 of my laboratory notebooks.

7q. Work relating to the ligation of the BstU/Xho-4.4 fragment and the Xho/Xca-1.35 fragment is described at production nos. 474 and 485 of my laboratory notebooks.

7r. Work relating to the ligation of two or three of the BamHI/SpHI-2.25 fragment, the SpHI/PmlI-1.5 fragment, and the PmlI/5'end-3 fragment to each other is described at production nos. 425, 458, 465-466, 468-473, 475, and 491 of my laboratory notebooks.

8. The fragments that are described in paragraphs 7a to 7s were later used to assemble full-length cDNA that encodes the genome of an RSV, which was used to rescue an infectious and replication-competent RSV. The full-length cDNA was genetically

manipulated to generate RSV cDNAs with deletions and insertions, which was used to rescue an infectious and replication-competent RSV with an insertion and/or deletion.

9. Exhibit F is a summary of the work described in the laboratory notebooks that are submitted herewith as Exhibits C to E. Each row in Exhibit F represents one day or, where the experiment was performed over several days, a row represents the corresponding period of time.

10. I declare that since the date of conception of the invention I was diligently working towards the reduction to practice of the invention. The only interruption of my work toward the reduction to practice in the laboratory of more than one week was during the two weeks immediately prior to filing of the Grand Parent application. However, during my absence from the laboratory, my technician, Lisa Paganini, was working on the ligation of the SphI/PmlI-1.5 kb fragment and the BamHI/SphI-2.25 kb fragments to each other in accordance with my instructions as indicated at production no. 491.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: March 24th 2004


DAVID K. CLARKE

Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees

MICHAEL N. TENG,¹ STEPHEN S. WHITEHEAD,¹ ALISON BERMINGHAM,¹ MARISA ST. CLAIRE,²
WILLIAM R. ELKINS,³ BRIAN R. MURPHY,¹ AND PETER L. COLLINS^{1*}

*Respiratory Viruses Section¹ and Experimental Primate Virology Section,³ Laboratory of Infectious Diseases,
National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, 20892, and Bioqual, Inc.,
Rockville, Maryland, 20850²*

Received 11 May 2000/Accepted 28 June 2000

Mutant recombinant respiratory syncytial viruses (RSV) which cannot express the NS1 and M2-2 proteins, designated rA2ΔNS1 and rA2ΔM2-2, respectively, were evaluated as live-attenuated RSV vaccines. The rA2ΔNS1 virus contains a large deletion that should have the advantageous property of genetic stability during replication in vitro and in vivo. In vitro, rA2ΔNS1 replicated approximately 10-fold less well than wild-type recombinant RSV (rA2), while rA2ΔM2-2 had delayed growth kinetics but reached a final titer similar to that of rA2. Each virus was administered to the respiratory tracts of RSV-seronegative chimpanzees to assess replication, immunogenicity, and protective efficacy. The rA2ΔNS1 and rA2ΔM2-2 viruses were 2,200- to 55,000-fold restricted in replication in the upper and lower respiratory tracts but induced a level of RSV-neutralizing antibody in serum that was only slightly reduced compared to the level induced by wild-type RSV. The replication of wild-type RSV in immunized chimpanzees after challenge was reduced more than 10,000-fold at each site. Importantly, rA2ΔNS1 and rA2ΔM2-2 were 10-fold more restricted in replication in the upper respiratory tract than was the *cpts248/404* virus, a vaccine candidate that retained mild reactogenicity in the upper respiratory tracts of 1-month-old infants. Thus, either rA2ΔNS1 or rA2ΔM2-2 might be appropriately attenuated for this age group, which is the major target population for an RSV vaccine. In addition, these results show that neither NS1 nor M2-2 is essential for RSV replication in vivo, although each is important for efficient replication.

Respiratory syncytial virus (RSV) is the leading etiologic agent of serious pediatric viral bronchiolitis and pneumonia worldwide and is responsible for approximately 100,000 hospitalizations and 4,500 deaths among infants and children in the United States per annum (7, 14, 25). In addition, RSV infection can cause severe respiratory illness in the elderly (23) and in immunocompromised individuals (28). To date, an effective licensed vaccine for RSV is not available despite the pressing need for such an agent.

Since 1967, our laboratory has focused on developing a live-attenuated RSV vaccine for intranasal administration. By mimicking a natural infection, such a vaccine should stimulate both cellular and humoral immunity and would obviate the potentiated disease that was observed with certain nonreplicating or subunit vaccines (7, 16, 24, 27). The intranasal route also partially abrogates the immunosuppressive effects of maternal antibodies present in the sera of young infants and stimulates both local and systemic immunity (10).

A number of live-attenuated RSV vaccine candidates have been developed by biological or recombinant methods and evaluated in animals and humans (8, 15, 16, 29, 30, 32). The most promising biologically derived candidate, a cold-passaged (*cp*) temperature-sensitive (*ts*) virus called *cpts248/404*, was evaluated in RSV-naïve 1- to 2-month-old infants and was found to be infectious, immunogenic, and protective against a second vaccine dose (33). However, some vaccinees experienced mild upper respiratory tract congestion, indicating that

further attenuation is necessary. In addition, virus isolated late during the course of infection from a single vaccinee showed partial phenotypic reversion and loss of an attenuating mutation. Thus, our strategy to develop improved live-attenuated vaccine candidates has been (i) to use recombinant methods to combine attenuating mutations identified in a panel of biologically derived attenuated viruses including *cpts248/404* and (ii) to develop new types of attenuating mutations by focusing on gene deletions which should be refractory to genetic reversion.

RSV is the prototype member of the *Pneumovirus* genus of the family *Paramyxoviridae*. Its genome is a single-stranded, negative-sense RNA of 15.2 kb that encodes 10 subgenomic mRNAs from which 11 proteins are translated. These proteins include the nucleocapsid N protein, phosphoprotein P, and large polymerase subunit L, which together comprise the minimal viral polymerase; fully processive transcription by the RSV polymerase requires the presence of the transcription antitermination factor M2-1 (6, 18, 19, 34). There are four envelope-associated proteins: the internal matrix (M) protein and three transmembrane surface proteins, namely, the attachment (G), fusion (F), and small hydrophobic (SH) proteins (7). Finally, RSV encodes two nonstructural proteins, NS1 and NS2, and also the M2-2 protein, whose status as structural or nonstructural is unknown. NS1 and M2-2 appear to have roles in RNA synthesis.

We previously described a reverse-genetics system for producing recombinant subgroup A RSV (rRSV) by coexpression of antigenomic RNA and the N, P, L, and M2-1 proteins from cotransfected plasmids (5). One application of this system has been to identify viral genes that can be deleted or silenced without ablating replication in vitro but are still necessary for

* Corresponding author. Mailing address: LID, NIAID, 7 Center Dr., MSC 0720, Bethesda, MD 20892-0720. Phone: (301) 496-4205. Fax: (301) 496-8312. E-mail: pcollins@niaid.nih.gov.

virus replication in vivo (4, 26). Deletion of the SH gene resulted in a virus, designated rA2ΔSH, that replicated in vitro with an efficiency equal to or slightly better than that of wild-type rRSV (rA2) and which was moderately attenuated in mice and chimpanzees (4, 29). rRSV from which the NS2 gene was deleted, designated rA2ΔNS2, exhibited reduced growth kinetics and a reduced yield of infectious virus in vitro and was markedly attenuated in mice and chimpanzees (26, 29). Similar in vitro properties were noted for a recombinant bovine RSV from which the NS2 gene was deleted (2). These two deletion mutations are now being incorporated into recombinant live-attenuated vaccine candidates for clinical evaluation.

More recently, the M2-2 open reading frame was silenced in rRSV (rA2ΔM2-2, previously designated rA2-K5) by mutating each of the three potential translational initiation codons and inserting a translation termination codon in each of the three reading frames (1). A second research group made a comparable virus in which M2-2 was silenced by deletion of most of its open reading frame, which resulted in a virus that appeared to be phenotypically similar to rA2ΔM2-2 (20). The rA2ΔM2-2 virus exhibited increased plaque size, reduced growth kinetics (though the final titer was similar to that of the wild type), and a partial shift in RNA synthesis from RNA replication to transcription (1). Thus, the M2-2 protein appears to be a regulatory protein that negatively regulates transcription and positively regulates RNA replication. In addition, an rRSV was constructed from which the NS1 gene was deleted by the removal of nucleotides 122 to 630 in the antigenomic cDNA, resulting in the joining of the upstream nontranslated region of NS1 to the translational initiation codon of NS2. This virus, designated rA2ΔNS1, exhibited reduced RNA replication, plaque size, and growth kinetics and an approximately 10-fold lower yield of infectious virus in vitro (M. N. Teng and P. L. Collins, submitted for publication). Other paramyxoviruses encode proteins, such as the V protein of Sendai virus, that are not essential for replication in vitro. However, ablation of expression of V by recombinant Sendai virus results in attenuation in vivo (22). It was suggested that this protein functioned to antagonize some aspect of the mouse's innate immune system. More recently, the V protein of simian virus 5 was shown to block signalling for both type I and type II interferon responses (13). Any of the RSV "accessory" proteins, including the NS1, NS2, M2-2, SH, and G proteins, are candidates for antagonizing host immune mechanisms.

In the present study, we evaluated the rA2ΔM2-2 and rA2ΔNS1 viruses for replication, immunogenicity, and protective efficacy in the upper and lower respiratory tracts of chimpanzees, the only experimental animal in which RSV replication and virulence approaches that observed in humans. The rA2ΔM2-2 and rA2ΔNS1 viruses described above were constructed in the original version of the antigenomic cDNA described by Collins et al. (5). All recombinant viruses that have been constructed for vaccine purposes in our laboratory contain two types of modification to this background: (i) the introduction of a set of six translationally silent restriction markers in the L gene, called the sites mutations, and (ii) two amino acid substitutions in the F protein, called the HEK mutations, which make the recombinant virus identical at the amino acid level to the wild-type RSV A2 parent from which the *cpts248/404* series of biological vaccine candidates was derived (21, 30). These mutations were shown to be phenotypically silent in chimpanzees (32). The rA2ΔNS1 virus used in this study was reconstructed in a sites-HEK background, in preparation for clinical evaluation, whereas the rA2ΔM2-2 virus is in the original genetic background, a difference that is not relevant for the present study (1, 30).

The rA2ΔNS1 and rA2ΔM2-2 viruses were administered individually to juvenile RSV-seronegative chimpanzees by combined intranasal and intratracheal inoculation, as described previously (11). Since both viruses were attenuated in vitro, we chose to inoculate the animals with 10^5 PFU per ml per site, which is a 10-fold higher concentration than that typically used to inoculate chimpanzees. To monitor virus replication in the upper and lower respiratory tracts, respectively, nasopharyngeal swabs and tracheal lavage samples were collected at intervals over 10 days postinfection and subsequently were assayed for virus titer. The mean peak virus titer was determined for each group (Table 1). The chimpanzees were monitored daily for rhinorrhea, a symptom of upper respiratory tract illness, and the mean peak score was determined for each group (Table 1). Due to the limited availability of RSV-seronegative chimpanzees, the number of animals per group was small, making it necessary to include controls from previous studies in which we had evaluated biologically derived RSV strain A2 (wild-type RSV A2), rA2, rA2ΔSH, rA2ΔNS2, and a recombinant version of the above-mentioned *cpts248/404* vaccine candidate (rA2cp248/404) (Table 1).

Levels of replication of rA2ΔNS1 and rA2ΔM2-2 were reduced more than 2,200-fold and more than 2,800-fold, respectively, in the upper respiratory tract compared to that of rA2 (Table 1). Shedding of rA2ΔNS1 or rA2ΔM2-2 was detected sporadically and at a low level beginning 2 to 7 days postinfection, and each animal shed virus over a period of 3 to 8 days (data not shown). Thus, the recovered virus was not carried over from the initial inoculum but represented replication near the level of detection over a period of several days. In the lower respiratory tract, the level of replication of rA2ΔNS1 was reduced more than 17,000-fold compared to that of rA2, while rA2ΔM2-2 was undetectable at all time points (greater than 55,000-fold reduction). It is important to note that the dose of rA2ΔNS1 and rA2ΔM2-2 used was 10-fold greater than that of rA2. Furthermore, both viruses were more attenuated than rA2cp248/404, which was given at the same dose, particularly in the case of rA2ΔM2-2, which was not recovered from the lungs of infected chimps. In addition, both rA2ΔNS1 and rA2ΔM2-2 were unusual in being equally restricted in the upper and lower respiratory tracts. In the upper respiratory tract, each virus was approximately 10-fold more restricted than *cpts248/404* and 175-fold more restricted than rA2ΔNS2. Since upper respiratory tract congestion was observed during clinical evaluation of the *cpts248/404* virus in 1- to 2-month-old infants (33) and since infants of that age are obligate nose breathers, mutations that confer a level of restriction of replication in the upper respiratory tract greater than that of *cpts248/404* would be desirable for inclusion in a live-attenuated vaccine virus. Animals receiving rA2ΔNS1 or rA2ΔM2-2 had slightly more rhinorrhea than those infected with rA2cp248/404, though still less than that of animals infected with a 10-fold smaller dose of rA2. While it is possible that the absence of NS1 or M2-2 resulted in a virus that retained a moderate level of virulence but replicated poorly, we think that this possibility is unlikely. Our experience is that quantitation of rhinorrhea and the comparison of such values from different studies performed at different times can be somewhat subjective and hence not completely reproducible. We anticipate that further evaluation, including clinical studies, will show that the amount of residual virulence associated with rA2ΔNS1 and rA2ΔM2-2 will reflect their greatly reduced replication.

Despite the highly restricted replication of these viruses, immunization with either rA2ΔNS1 or rA2ΔM2-2 induced a level of RSV-neutralizing antibody in serum that was within threefold of that induced by rA2cp248/404 (Table 1). Further-

TABLE 1. rA2ΔNS1 and rA2ΔM2-2 are highly attenuated in both the upper and lower respiratory tracts of chimpanzees but are highly immunogenic

Virus used to infect chimpanzees ^a	No. of animals	Dose ^b (per site, log ₁₀ PFU)	Mean peak virus titer ^c (log ₁₀ PFU/ml) ± SE (Duncan grouping)		Mean peak rhinorrhea score ^d (range, 0–4)	Mean neutralizing antibody titer in serum ^e (reciprocal log ₂)	
			Nasopharyngeal swab	Tracheal lavage		Day 0	Day 28
Wild-type RSV A2 ^f	2	4.0	5.0 ± 0.35 (A)	5.5 ± 0.40 (A)	3.0	<3.3	11.2
rA2 ^g	2	4.0	4.9 ± 0.15 (A)	5.4 ± 0.05 (A)	2.5	<3.3	10.5
rA2ΔSH ^g	3	4.0	4.6 ± 0.10 (A)	3.8 ± 0.31 (B)	1.0	<3.3	10.2
rA2ΔNS2 ^g	4	4.0	3.8 ± 0.41 (B)	1.4 ± 0.29 (C)	1.0	3.4	10.6
rA2cp248/404 ^g	4	5.0	2.5 ± 0.25 (C)	1.4 ± 0.37 (C)	0.8	3.4	10.6
rA2ΔNS1	4	5.0	1.6 ± 0.12 (D)	1.2 ± 0.43 (C)	2.0	<3.3	9.8
rA2ΔM2-2	4	5.0	1.5 ± 0.09 (D)	<0.7	1.8	<3.3	9.1

^a All recombinant-derived viruses contain the sites and HEK mutations (see the text), except for rA2ΔM2-2.

^b Chimpanzees were inoculated by the intranasal and intratracheal routes with the indicated amount of virus in a 1-ml inoculum per site.

^c Nasopharyngeal swab samples were collected daily for 10 days, and tracheal lavage samples were collected on days 2, 5, 6, 8, and 10. Mean peak titers were calculated and assigned to statistically similar groups by Duncan's multiple-range test ($\alpha = 0.05$). Means in each column with different letters are significantly different.

^d The amount of rhinorrhea was estimated daily and assigned a score (0 to 4) that indicated extent and severity. Scores indicate severe (4), moderate (3), mild (2), trace (1), or no (0) rhinorrhea. Shown are the mean peak scores.

^e Serum RSV-neutralizing antibody titers were determined by a complement-enhanced 60% plaque reduction assay using wild-type RSV A2 and HEp-2 cell monolayer cultures incubated at 37°C. RSV-seronegative chimpanzee serum used as a negative control had a neutralizing antibody titer of <3.3 log₂ reciprocal. Adult human serum used as a positive control had a neutralizing antibody titer of 11.4 log₂ reciprocal.

^f Historic controls from the study of Crowe et al. (10).

^g Data from the study of Whitehead et al. (29).

more, animals previously infected with either rA2ΔNS1 or rA2ΔM2-2 were highly resistant to the replication of wild-type RSV administered intranasally and intratracheally 56 days postimmunization (Table 2). The levels of protection in both cases were similar in the upper respiratory tract and somewhat lower in the lower respiratory tract than that seen with *cp*ts248/404, both in mean peak titer and in mean days of shedding.

The challenge in developing a live-attenuated RSV vaccine is to eliminate residual virulence without compromising immunogenicity. Observations to date indicate that the severity of RSV disease is closely related to the level of RSV replication in the respiratory tract. It is possible that one or more attenuating mutations that reduce virulence through another mechanism will be identified; indeed, it was hoped that deletion of one or more of the nonessential RSV proteins, such as those described in the present paper, might reveal such a virulence

factor. However, a factor of this nature has not yet been identified for RSV. Thus, the present method for attenuating RSV is to reduce its level of replication, which unfortunately can reduce its immunogenicity due to the reduced production of antigen. The attenuating mutations that we have identified to date include (i) a set of five amino acid substitutions in the N, F, and L proteins that were identified in *cp*RSV and that confer attenuation in chimpanzees and humans (9, 16, 32); (ii) a series of amino acid substitutions in the L protein and a nucleotide substitution in the gene-start signal of the M2 gene, which were identified in biologically derived *ts* derivatives of *cp* RSV and which each confer the *ts* and attenuation phenotypes (12, 15, 21, 30); and (iii) deletion of individual or combinations of RSV genes such as the SH and NS2 genes (4, 26). Bovine RSV genes have also been used to confer attenuation based on host range restriction (3). Here, we add two additional knock-

TABLE 2. Infection of chimpanzees with rA2ΔNS1 or rA2ΔM2-2 induced significant protection against subsequent challenge with wild-type RSV A2 in the upper and lower respiratory tracts

Immunizing virus	Inoculum dose ^a (log ₁₀ PFU/ml)	No. of animals	Replication of RSV challenge virus at the indicated site ^b				Mean peak rhinorrhea score
			Nasopharynx		Trachea		
			Mean no. of days of shedding ± SE	Mean peak titer ^c ± SE	Mean no. of days of shedding ± SE	Mean peak titer ± SE	
rA2ΔNS1	5.0	4	2.8 ± 0.75	1.7 ± 0.46	1.0 ± 0.41	1.8 ± 0.73	1.0
rA2ΔM2-2	5.0	4	3.5 ± 0.87	2.3 ± 0.71	1.0 ± 0.71	1.7 ± 0.63	1.0
rA2ΔNS2 ^d	4.0	4	ND	1.9 ± 0.30	ND	2.2 ± 0.77	1.0
<i>cpts</i> 248/404 ^e	4.7	2	3.5 ± 0.50	2.3 ± 0.25	0	<0.7	1.0
None ^e		2	8.5 ± 0.50	5.0 ± 0.35	6.0 ± 1.0	4.8 ± 0.30	3.0

^a Each virus was initially administered at the indicated dose in a 1.0-ml inoculum given intranasally and intratracheally.

^b On day 56, chimpanzees were challenged with wild-type RSV A2 administered at a dose of 10⁴ PFU/ml in a 1.0-ml inoculum given intranasally and intratracheally. Nasopharyngeal swab samples were collected daily for 12 days, and tracheal lavage samples were collected on days 2, 5, 6, 8, and 12. ND, not determined.

^c Mean peak titers (log₁₀ PFU/ml) were calculated by using the peak virus titer achieved in each animal.

^d Data from the study of Whitehead et al. (29).

^e Historic control animals from the study of Crowe et al. (10) were used.

out mutations to the list, namely, the deletion of NS1 and the silencing of the M2-2 open reading frame.

Among the mutant viruses shown in Table 1, the order of increasing attenuation in seronegative juvenile chimpanzees was rA2ΔSH < rA2ΔNS2 < rA2cp248/404 < rA2ΔNS1 < rA2ΔM2-2. All viruses provided similar, high levels of protection against challenge with wild-type RSV (Table 2). Thus, rA2ΔNS1 and rA2ΔM2-2 each have the desired property of being slightly more attenuated than rA2cp248/404, the recombinant version of *cp248/404*, which was slightly too reactogenic in RSV-naïve 1- to 2-month-old infants, as mentioned above (33). The finding that rA2ΔM2-2 is slightly more attenuated than rA2ΔNS1 increases the chances that one of these viruses will have an optimal level of attenuation. The seronegative juvenile chimpanzee is somewhat less permissive to RSV replication and disease than is the RSV-naïve human infant. Thus, whether rA2ΔNS1, rA2ΔM2-2, or both have an appropriate level of attenuation can be determined only by clinical trials with the target vaccine population, 1- to 2-month-old infants.

Deletion mutants should be extremely stable both in vitro and in vivo, thus making them attractive candidates for vaccine development. This property might be important in light of the finding that one infant who had been vaccinated with *cp248/404* shed virus that exhibited a partial reversion (33). A low level of genetic instability in an RSV vaccine likely would not be a problem in normal individuals, particularly considering the high prevalence of fully virulent wild-type RSV. However, vaccine virus might have prolonged replication in immunocompromised individuals. Thus, it would be desirable to engineer a recombinant vaccine virus to contain attenuating mutations that cannot revert.

Although the major target for an RSV vaccine is the 1- to 2-month-old infant, a second target is the elderly. The *cp248/404* vaccine candidate, which was insufficiently attenuated in the RSV-naïve infant, was found to be overattenuated in the RSV-experienced adult (17). Thus, a live-attenuated vaccine for RSV-naïve infants will need to be more attenuated than one for use in adults. Since the rA2ΔNS1 and rA2ΔM2-2 viruses are similar to *cp248/404* in their levels of replication, they likely will be too attenuated to be useful as an adult vaccine. However, each virus is appropriate for further evaluation as a pediatric RSV vaccine, either as currently constructed or with the inclusion of a single or a combination of additional attenuating mutations. It should be noted that if either candidate vaccine proves satisfactory, a partner subgroup B candidate can be rapidly generated by replacing the F and G glycoproteins (31).

We thank Robert Chanock for critical review.

This work is part of a continuing program of research and development with Wyeth Lederle Vaccines through CRADA no. AI-000087 and AI-000099.

REFERENCES

- Bermingham, A., and P. L. Collins. 1999. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. *Proc. Natl. Acad. Sci. USA* 96:11259-11264.
- Buchholz, U. J., S. Finke, and K. K. Conzelmann. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. *J. Virol.* 73:251-259.
- Buchholz, U. J., H. Granzow, K. Schuldt, S. S. Whitehead, B. R. Murphy, and P. L. Collins. 2000. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. *J. Virol.* 74:1187-1199.
- Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. *J. Virol.* 71:8973-8982.
- Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. *Proc. Natl. Acad. Sci. USA* 92:11563-11567.
- Collins, P. L., M. G. Hill, J. Cristina, and H. Grosfeld. 1996. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. *Proc. Natl. Acad. Sci. USA* 93:81-85.
- Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), *Fields virology*, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
- Collins, P. L., S. S. Whitehead, A. Bukreyev, R. Fearn, M. N. Teng, K. Juhász, R. M. Chanock, and B. R. Murphy. 1999. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. *Adv. Virus Res.* 54:423-451.
- Connors, M., J. E. Crowe, Jr., C.-Y. Firestone, B. R. Murphy, and P. L. Collins. 1995. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. *Virology* 208:478-484.
- Crowe, J. E., Jr., P. T. Bui, G. R. Siber, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. *Vaccine* 13:847-855.
- Crowe, J. E., Jr., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. *Vaccine* 12:783-790.
- Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. *Vaccine* 12:691-699.
- Didcock, L., D. F. Young, S. Goodbourn, and R. E. Randall. 1999. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. *J. Virol.* 73:9928-9933.
- Dudas, R. A., and R. A. Karron. 1998. Respiratory syncytial virus vaccines. *Clin. Microbiol. Rev.* 11:430-439.
- Firestone, C. Y., S. S. Whitehead, P. L. Collins, B. R. Murphy, and J. E. Crowe, Jr. 1996. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) *cp248/404* live attenuated virus vaccine candidate. *Virology* 225:419-422.
- Friedewald, W. T., B. R. Forsyth, C. B. Smith, M. A. Gharpure, and R. M. Chanock. 1968. Low-temperature-grown RS virus in adult volunteers. *JAMA* 203:690-694.
- Gonzalez, I. M., R. A. Karron, M. Eichelberger, E. E. Walsh, V. W. Delagarza, R. Bennett, R. M. Chanock, B. R. Murphy, M. L. Clements-Mann, and A. R. Falsey. 2000. Evaluation of the live attenuated *cp248/404* RSV vaccine in combination with a subunit RSV vaccine (PF2) in healthy young and older adults. *Vaccine* 18:1763-1772.
- Grosfeld, H., M. G. Hill, and P. L. Collins. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. *J. Virol.* 69:5677-5686.
- Hardy, R. W., and G. W. Wertz. 1998. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. *J. Virol.* 72:520-526.
- Jin, H., X. Cheng, H. Z. Zhou, S. Li, and A. Seddiqui. 2000. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. *J. Virol.* 74:74-82.
- Juhász, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated *cp2530*, results from a single amino acid substitution in the L protein. *J. Virol.* 71:5814-5819.
- Kato, A., K. Kiyotani, Y. Sakai, T. Yoshida, and Y. Nagai. 1997. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. *EMBO J.* 16:578-587.
- Mlinaric-Galinovic, G., A. R. Falsey, and E. E. Walsh. 1996. Respiratory syncytial virus infection in the elderly. *Eur. J. Clin. Microbiol. Infect. Dis.* 15:777-781.
- Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, Jr., P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. *Virus Res.* 32:13-36.
- Shay, D. K., R. C. Holman, R. D. Newman, L. L. Liu, J. W. Stout, and L. J. Anderson. 1999. Bronchiolitis-associated hospitalizations among US chil-

- dren, 1980–1996. *JAMA* 282:1440–1446.
26. Teng, M. N., and P. L. Collins. 1999. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. *J. Virol.* 73:466–473.
 27. Waris, M. E., C. Tsou, D. D. Erdman, D. B. Day, and L. J. Anderson. 1997. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. *J. Virol.* 71:6935–6939.
 28. Wendt, C. H., and M. I. Hertz. 1995. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. *Semin. Respir. Infect.* 10:224–231.
 29. Whitehead, S. S., A. Bukreyev, M. N. Teng, C. Y. Firestone, M. St. Claire, W. R. Elkins, P. L. Collins, and B. R. Murphy. 1999. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. *J. Virol.* 73:3438–3442.
 30. Whitehead, S. S., C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. *Virology* 247:232–239.
 31. Whitehead, S. S., M. G. Hill, C. Y. Firestone, M. St. Claire, W. R. Elkins, B. R. Murphy, and P. L. Collins. 1999. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. *J. Virol.* 73:9773–9780.
 32. Whitehead, S. S., K. Juhasz, C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. *J. Virol.* 72:4467–4471.
 33. Wright, P. F., R. A. Karron, R. B. Belshe, J. Thompson, J. E. Crowe, Jr., T. G. Boyce, L. L. Halburnt, G. W. Reed, S. S. Whitehead, E. L. Anderson, A. E. Wittek, R. Casey, M. Eichelberger, B. Thumar, V. B. Randolph, S. A. Udem, R. M. Chanock, and B. R. Murphy. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus (RSV) vaccine candidate in infancy. *J. Infect. Dis.*, in press.
 34. Yu, Q., R. W. Hardy, and G. W. Wertz. 1995. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal *trans*-acting requirements for RNA replication. *J. Virol.* 69:2412–2419.